tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:722 Stock Latest News

Antengene Narrows Losses on Cost Cuts as Revenue Climbs in 2025
Company AnnouncementsAntengene Narrows Losses on Cost Cuts as Revenue Climbs in 2025
3d ago
Antengene Schedules Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
Antengene Schedules Board Meeting to Approve 2025 Annual Results
14d ago
Antengene Grants UCB Global Rights to ATG-201 in Autoimmune Disease Deal Worth Up to USD1.2 Billion
PremiumCompany Announcements
Antengene Grants UCB Global Rights to ATG-201 in Autoimmune Disease Deal Worth Up to USD1.2 Billion
20d ago
Antengene’s XPOVIO® Gains New Approval in Malaysia for Lymphoma Treatment
PremiumCompany Announcements
Antengene’s XPOVIO® Gains New Approval in Malaysia for Lymphoma Treatment
3M ago
Antengene Corporation Enhances Governance with New Committee
PremiumCompany Announcements
Antengene Corporation Enhances Governance with New Committee
3M ago
Antengene’s XPOVIO® Gains New Approvals in Hong Kong
PremiumCompany AnnouncementsAntengene’s XPOVIO® Gains New Approvals in Hong Kong
4M ago
Antengene Secures IND Approval for ATG-022 Study in China
Premium
Company Announcements
Antengene Secures IND Approval for ATG-022 Study in China
4M ago
Antengene Announces Share Repurchase Plan to Boost Shareholder Value
Premium
Company Announcements
Antengene Announces Share Repurchase Plan to Boost Shareholder Value
7M ago
Antengene Reports Reduced Losses Despite Revenue Dip in H1 2025
PremiumCompany Announcements
Antengene Reports Reduced Losses Despite Revenue Dip in H1 2025
7M ago
Antengene’s ATG-022 Receives Breakthrough Therapy Designation
PremiumCompany Announcements
Antengene’s ATG-022 Receives Breakthrough Therapy Designation
7M ago
Antengene Schedules Board Meeting to Review Interim Results
PremiumCompany Announcements
Antengene Schedules Board Meeting to Review Interim Results
7M ago
Antengene’s XPOVIO® Gains Approval in China for Multiple Myeloma Treatment
PremiumCompany Announcements
Antengene’s XPOVIO® Gains Approval in China for Multiple Myeloma Treatment
8M ago
Antengene Corporation Announces Change of Hong Kong Business Address
PremiumCompany AnnouncementsAntengene Corporation Announces Change of Hong Kong Business Address
9M ago
Antengene Corporation Successfully Passes All Resolutions at AGM
Premium
Company Announcements
Antengene Corporation Successfully Passes All Resolutions at AGM
9M ago
Antengene Corporation Announces 2025 AGM with Key Resolutions
Premium
Company Announcements
Antengene Corporation Announces 2025 AGM with Key Resolutions
11M ago
Antengene Announces Share Repurchase Plan to Boost Shareholder Value
PremiumCompany Announcements
Antengene Announces Share Repurchase Plan to Boost Shareholder Value
12M ago
Antengene Reports Revenue Growth and Reduced Losses for 2024
PremiumCompany Announcements
Antengene Reports Revenue Growth and Reduced Losses for 2024
1y ago
Antengene Corporation to Review Annual Financial Results
PremiumCompany Announcements
Antengene Corporation to Review Annual Financial Results
1y ago
Antengene’s XPOVIO® Gains Approval in Indonesia for Multiple Indications
PremiumCompany Announcements
Antengene’s XPOVIO® Gains Approval in Indonesia for Multiple Indications
1y ago
Antengene Expands AI Investment to Boost T-Cell Engager Development
PremiumCompany AnnouncementsAntengene Expands AI Investment to Boost T-Cell Engager Development
1y ago
Antengene’s XPOVIO Gains Taiwan Health Insurance Approval
Premium
Company Announcements
Antengene’s XPOVIO Gains Taiwan Health Insurance Approval
1y ago
Antengene’s XPOVIO Gains Key Inclusion in China
Premium
Company Announcements
Antengene’s XPOVIO Gains Key Inclusion in China
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >